Life Technologies Delivers Enhanced Genomic Analysis Technology for Large-Scale Resequencing Projects
News Oct 26, 2009
Applied Biosystems, part of Life Technologies Corporation has announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to performing mainstream sequencing of personal genomes for clinical research and personalized medicine.
According to Applied Biosystems, the technical enhancements to SOLiD 3 Plus include higher throughput, decreased run costs, and faster data analysis which deliver on a roadmap that enables scientists to sequence entire genomes in a cost-effective and easy manner.
The SOLiD 3 Plus System designed to generate more than 60 gigabases of mappable sequence data per run, at a 20% lower cost per sequencing run than previously possible. The combination of increased throughput, which equates to an approximate 50% decrease in cost per gigabase, shorter run times, and improved data analysis makes the SOLiD technology the ideal choice for large-scale resequencing genomic projects.
An advanced software solution, BioScope™, has been introduced and provides an integrated framework for data analysis, which allows researchers to benefit from smaller data files sizes while delivering faster mapping times. The addition of BioScope enables researchers to export data into a standard base sequence format, enabling the combination of data from multiple sequencing platforms into a single project-based analysis, and allows direct comparison of data from multiple next-generation sequencing platforms. This has proven to be beneficial in large-scale genomic studies, such as the 1000 Genomes Project.
Dr. Hans Lehrach, head of the Vertebrate Genomics Department at the Max Planck Institute for Molecular Genetics, is currently utilizing four SOLiD Systems for the 1000 Genomes Project and various other projects. Dr. Lehrach’s work is focused on the fields of cancer genomics, genome analysis and systems biology with particular interest in cellular and molecular mechanisms of cancer and other diseases. His research team currently uses the SOLiD System for a range of genomic studies, including whole genome resequencing, methylation analysis, miRNA and targeted resequencing.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.